poststatin

structure given in first source p.960; inhibitor of prolyl endopeptidase; produced by Streptomyces viridochromogenes MH534-30F3

Also Known As:

valyl-valyl-3-amino-2-oxovaleryl-leucyl-valine; L-Valine, L-valyl-L-valyl-2-oxo-L-3-aminopentanoyl-D-leucyl-

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

1.	Cariou, Bertrand: 1 article (01/2018)
2.	Yvan-Charvet, Laurent: 1 article (01/2018)
3.	Crook, Martin A: 1 article (11/2017)
4.	Kohli, Monika: 1 article (11/2017)
5.	MacMahon, Zofia: 1 article (11/2017)
6.	Patel, Kinjal: 1 article (11/2017)
7.	Ramachandran, Radha: 1 article (11/2017)
8.	Reynolds, Timothy M: 1 article (11/2017)
9.	Wierzbicki, Anthony S: 1 article (11/2017)
10.	Davis, Matthew A: 1 article (11/2015)

1.	Rhabdomyolysis 11/01/2017 - "PCSK-9 therapy was effective and safe in patients with increased lipoprotein (a), diagnosed muscle diseases (including myopathies and muscular dystrophy) or poststatin rhabdomyolysis, nephrotic syndrome or HIV disease. "
2.	Nephrotic Syndrome (Syndrome, Nephrotic) 11/01/2017 - "PCSK-9 therapy was effective and safe in patients with increased lipoprotein (a), diagnosed muscle diseases (including myopathies and muscular dystrophy) or poststatin rhabdomyolysis, nephrotic syndrome or HIV disease. "
3.	Muscular Dystrophies (Muscular Dystrophy) 11/01/2017 - "PCSK-9 therapy was effective and safe in patients with increased lipoprotein (a), diagnosed muscle diseases (including myopathies and muscular dystrophy) or poststatin rhabdomyolysis, nephrotic syndrome or HIV disease. "
4.	Muscular Diseases (Myopathy) 11/01/2017 - "PCSK-9 therapy was effective and safe in patients with increased lipoprotein (a), diagnosed muscle diseases (including myopathies and muscular dystrophy) or poststatin rhabdomyolysis, nephrotic syndrome or HIV disease. "
5.	Atherosclerosis 01/01/2018 - "Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies." 11/01/2015 - "These results suggest that SOAT2-selective inhibitors such as PRD125 have a high potential as poststatin agents for treatment and/or prevention in patients with atherosclerosis and hypercholesterolemia. "

1.	Lipoprotein(a)
2.	Salts
3.	Kinins
4.	ebelactone B
5.	1,11- O- o- methylbenzylidene- 7- O- p- cyanobenzoyl- 1,7,11- trideacetylpyripyropene A

1.	Therapeutics